氨溴索佐治哮喘性支气管炎98例疗效观察

目的探讨氨溴索佐治哮喘性支气管炎的临床疗效。方法98例哮喘性支气管炎患者随机分为对照组和观察组，每组均为49例。对照组给予止咳、解痉、吸氧、平喘、抗感染等常规治疗；观察组在对照组基础上辅以氨溴索。比较两组疗效、临床症状消失时间、肺功能改善及炎性因子水平变化情况。结果观察组显效率为71．43％，显著高于对照组的51．02％（X^2=3．78，P〈0．05），观察组总有率为91．84％，显著高于对照组的71．43％（X^2=3．15，P〈0．05）；观察组咳嗽、喘息、痰鸣、湿啰音和哮鸣音等临床症状消失时间显著早于对照组（P〈0．05）；观察组治疗后FEV1和PEFR水平分别为（2．46＋0．51）L和（5．81＋1．70）L／s，显著高于观察组治疗前和对照组治疗后水平（P〈0．05）；观察组治疗后IL-8、CRP和TNF-α水平分别为（110．13±17．40）ng／L、（5．92±1．88）ng／L和（89．77±21．30）ng／L，显著低于观察组治疗前和对照组治疗后水平（P〈0．05）。结论常规治疗基础上联合氨溴索佐治哮喘性支气管炎能显著改善患者肺功能，降低炎性因子水平，促进患者早日康复，临床疗效显著优于常规治疗。

Observation of the effect of ambroxol on asthmatic bronchitis in 98 cases

Objective To investigate the clinical effect of ambroxol in treatment of asthmatic bronchitis. Methods Ninety-eight cases of asthmatic bronchitis were randomly divided into control group and observation group, with 49 cases in each. The conventional treatments, such as anti-coughing, spasmolysis, oxygen therapy, anti- asthma and anti-infection, were given in the control group. Besides, the ambroxol was added to the observation group. And then the clinical effects, remission time of clinical symptoms, improvement of lung function and changes in in- flammatory factor levels between two groups were compared. Results The effective rate in the observation group was 71.43%, which was significantly higher than that in the control group with 51.02% （X^2=3.78, P〈0.05）. The total effective rate was 91.84%, which was significantly higher than that of the control group with 71.43% （X2=3.15, P〈0.05）. The remission time of clinical symptoms of cough, phlegm, wheezing, wet rales and wheezes in the observation group was significantly shorter than those in the control group （P〈0.05）. In the observation group, the FEV1 and PEFR levels after treatment were （2.46±0.51） L and （5.81±1.70） L/s respectively, which were significantly higher than those before the treatment and in the control group after treatment （P〈0.05）. The levels of IL-8, CRP and TNF-α after treatment were （110.13±17.40） ng/L, （5.92±1.88） ng/L and （89.77±21.30） ng/L respectively, which were significantly lower than those before treatment and in the control group after treatment （P〈0.05） level. Conclusion Treatment of the asthmatic bronchitis with Ambroxol combined with conventional treatment could significantly improve the pulmonary function, reduce the levels of inflammatory factors, and promote an earlier recovery of patients, which was superior to conventional therapy in the clinical efficacy.